*ANNOUNCES NEW COLLABORATION WITH AMYLYX PHARMACEUTICALS
*COLLABORATION TO DEVELOP NOVEL LONG-ACTING GLP-1 RECEPTOR ANTAGONIST
*WILL RECEIVE UPFRONT AND RESEARCH PAYMENTS
*MAY RECEIVE OVER $50 MILLION IN SUCCESS-BASED DEVELOPMENT, COMMERCIALIZATION MILESTONES PLUS MID-SINGLE DIGIT ROYALTIES ON WORLDWIDE NET SALES
((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))
Source Date/Time = 30-DEC-202412:30:01.46 GMT